“EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients With Postsurgical Recurrence ”. Journal of Cancer Research Updates 1, no. 1 (January 28, 2012):  102–107. Accessed May 5, 2026. https://www.neoplasiaresearch.com/index.php/jcru/article/view/380.